Wells Fargo
VRDN icon

Wells Fargo’s Viridian Therapeutics VRDN Stock Holding History

Wells Fargo’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,100
Closed -$40.3K – 7288
2024
Q4 		$40.3K Buy
+2,100
New +$45.7K ﹤0.01% 5560

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wells Fargo's VRDN Position: Q1 2026 in Review

Wells Fargo reduced its Viridian Therapeutics (VRDN) stake by 37% in Q1 2026, selling an estimated $1.61M and leaving 93,204 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #3342.

Wells Fargo first reported a position in VRDN in Q3 2017 and has held it in 32 quarters since. The position peaked at $4.58M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Wells Fargo held 93,204 shares of Viridian Therapeutics worth $1.82M as of Q1 2026.
  • Wells Fargo sold 54,112 Viridian Therapeutics shares in Q1 2026, an estimated $1.61M.
  • Viridian Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3342 holding.
  • Wells Fargo first reported a position in Viridian Therapeutics in Q3 2017 and has held it in 32 quarters since.
  • Wells Fargo's Viridian Therapeutics position peaked at $4.58M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.